BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A

• Main Authors: Puppe, J, Drost, R, Liu, X, Joosse, S.A, Evers, B, Cornelissen-Steijger, P, Nederlof, P, Yu, Q, Jonkers, J, van Lohuizen, M, Pietersen, A.M
• Other Authors: PHYSIOLOGY
• Format: Article
• Published: 2020
• Subjects: 3 deazaneplanocin A; BRCA1 protein; transcription factor EZH2; 3 deazaneplanocin; 3-deazaneplanocin; adenosine; BRCA1 protein, human; drug derivative; Ezh2 protein, mouse; histone lysine methyltransferase; hybrid protein; messenger RNA; RNA; small interfering RNA; animal cell; animal experiment; animal model; article; breast cancer; cancer cell culture; cancer inhibition; cell differentiation; controlled study; drug sensitivity; gene mutation; gene overexpression; gene repression; genetic analysis; heterozygote; human; human tissue; immunohistochemistry; mouse; nonhuman; phenotype; protein expression; animal; biosynthesis; breast tumor; DNA repair; drug antagonism; drug delivery system; drug effect; female; gene silencing; genetics; metabolism; mutation; pathology; physiology; tumor cell line; tumor suppressor gene; Adenosine; Animals; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; DNA Repair; Drug Delivery Systems; Female; Gene Knockdown Techniques; Genes, BRCA1; Histone-Lysine N-Methyltransferase; Humans; Mice; Mutation; Recombinant Fusion Proteins; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/183273
• Institution: National University of Singapore

10.1186/bcr2354